Company news

Intellia Therapeutics, Inc. news in 2026

Intellia Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

November 12, 2026

Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

November 10, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 6, 2026

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

November 5, 2026

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

November 4, 2026

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

November 3, 2026

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

October 29, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 28, 2026

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

October 13, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

September 8, 2026

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

September 4, 2026

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

September 4, 2026

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

July 30, 2026

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

June 1, 2026

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 11, 2026

Intellia Announces Proposed Public Offering of Common Stock

April 27, 2026

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

April 27, 2026

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

April 27, 2026

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

April 24, 2026

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

March 3, 2026

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

March 2, 2026

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

February 26, 2026

Intellia Therapeutics to Participate in Upcoming Investor Conferences

February 23, 2026

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

February 20, 2026

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

February 19, 2026

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

January 26, 2026

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 1, 2026

Calls in 2026

Decks in 2026